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We have recently described a series ofhumanfetal cloned celllines thatexpress
CD3 proteins but not the a/# T cell receptor (TCR) (1). One of these clones,
termed F6C7, was used for mice immunizations. An mAb, designatedanti-NKFi
was found to identify on F6C7 lymphocytes a CD3-associated y chain (2, 3)
expressed either as a homodimer or possibly as part ofan heterodimer (note that
a S chain has remained undetected on F6C7 cells). Anti-NKFi was shown to have
a highly restricted clonotypic reactivity and could not therefore be used for
characterization oflymphocyte subpopulations with a TCR-y complex. Here, we
describe a novel mAb, anti-Ti-yA, which immunoprecipitates the same y protein
as anti-NKFi. However, the Ti-yA determinant corresponds to a public epitope
ofthis molecule, the expression ofwhich delineates a unique subset accounting
for ^-3% of human circulating lymphocytes.
Materials and Methods
mAbs andImmunofuorescence Analyses.
￿
Anti-Ti-yA was produced in mice after immu-
nization with a CD3+, WT31 - cloned cell line derived from peripheral blood of a healthy
adult individual. Cell fusions were performed according to a standard method described
previously (2). Anti-Ti-yA is of the IgG2a subclass. BMA 031 mAb was kindly provided
by Dr. Kurrle from the Behring Co. (Marburg, Federal Republic of Germany). This
reagent recognizes a monomorphic determinant of the Ti a/# receptor (4). All other
antibodies used in this study have been extensively characterized. Immunofluorescence
(IF) experiments were performed on freshly drawn peripheral blood from healthy adult
individuals. Nonadherent cells were treated for 30 min with either fluoresceinated anti-
Ti-yA aloneor anti-Ti-yA plus, individually, anti-CD2, -CD3, -CD4, -CD5, -CD6, -NKH 1,
-IamAbcoupledto phycoerythrin(PE), kindly provided by theCoultronics Co.(Margency,
France). For the comparative analysis of anti-Ti-yA reactivity in peripheral blood, we
used OKT3 (Ortho Pharmaceuticals, Raritan, NJ)and BMA 031 (Behring Co.). 3.0 x 10'
cells were analyzed in each sample on an Epics C instrument (Coulter Electronics, Inc.,
Hialeah, FL). Control reagents were FITC-IgG and PE-IgG.
Immunoprecipitations. F6C7 cells were surface labeled with '251 using a standard
lactoperoxidase method (2). After several steps of preclearing with Staphylococcus A
suspension as well as irrelevant antibodies, specific precipitations were carried out for 6 h
at 4°C with either anti-NKFi or anti-Ti-yA coupled to protein A-Sepharose beads.
Samples were then retreated twice, for 4 h, with the same antibodies before overnight
precipitation with the reciprocal mAb. SDS-PAGE was performed using 9% polyacryl-
amide gels either under nonreducing conditions or under reducing conditions after
addition of 5% 2-ME.
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Results and Discussion
FIGURE 1 . Immunoprecipitations
of NKFi and Ti-,yA molecules . Im-
munoprecipitations were performed
as described in Materials and Meth-
ods section . Lanes a-d, nonreduced,
lanes e-h, reduced after addition of
2-ME . Radiolabeled standards of var-
ious molecular masses were run in
parallel with immunoprecipitates .
Anti-Ti-yA Recognizes the Same Molecule as Anti-NKFi.
￿
Mice were immunized
with a CD3+, WT31 - , NIKE- , clone derived from peripheral blood ofan adult
donor . Among a large series of hybridoma supernatants, one reacted with the
previously described F6C7 cells (1-3) and not with a conventional cloned T
lymphocyte expressing an a/,B heterodimer . The mAb secreted by this hybri-
doma, termed anti-Ti-yA, recognized an antigenic determinant comodulating
with CD3 and NKFi on the surface of F6C7 lymphocytes (not shown) . Thus,
experiments were performed to compare the molecules immunoprecipitated
from F6C7 cells by anti-Ti-yA and anti-NKFi . As previously reported, NKFi
resolved in SDS-PAGE analysis as one 85 kD band undernonreducing conditions
(Fig. 1 a) and as two bands at 44 and 41 kD under reducing conditions (Fig . 1 e) .
The anti-Ti-yA-precipitated material showed a virtually superimposable electro-
phoretic mobility (Fig . 1, b and f) . Sequential precipitations confirmed the
identity between NKFi and Ti-7A molecules because there was no material
further recognized by anti-NKFi when samples were precleared with anti-Ti--YA
(Fig. 1 c, nonreduced ; lane g, reduced) and reciprocally (lane d, nonreduced ; lane
h, reduced) . Because it was previously shown (3) that both the 44 and 41 kD
NKFi bands are bound by a rabbit heteroantiserum specific for a 20-amino-acid
peptide encoded by the first exon of the C71 gene, we concluded here that anti-
Ti-yA recognizes a TCR y chain complex .
Anti-Ti-yA Defines a Subset ofPeripheral Blood Lymphocytes .
￿
We tested anti-Ti-
7A reactivity against a series of seven CD3'} , WT31- , NKFi- cloned cell lines
derived from peripheral blood of several adult donors . Five out of seven were
found to be Ti-yA' . Given this relatively broad distribution, it was possible that
anti-Ti-yA would define a detectable subpopulation of peripheral blood lympho-
cytes . Analysis of 30 individuals revealed that ^-3% of lymphocytes are Ti-yA',1194
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TABLE I
Characterization of the Ti-yA Subset by Double-color Immunofluorescence Analysis
Nonadherent lymphocytes were treated for 30 minwith either fluoresceinated anti-Ti-yA alone or anti-Ti-yA plus,
individually, anti-CD2, -CD3, -CD4, -CD5, -CD6, -NKH 1, or -la mAbcoupled to PE. Control reagents were FITC-
IgG and PE-IgG. 3.0 x 10' cells were analyzed in each sample. Numbers represent ratio x 100, rounded to the
nearest integer. A: Ratio between number of positive cells with one mAb and total number of cells analyzed. B:
Ratio between number of double-fluorescent cells (that is positive with both anti-Ti-yA and the indicated PE-
coupled antibody) and total number of cells analyzed. C: Ratio between number of double-fluorescent cells and
total number of cells positive with PE-coupled antibody. D: Ratio between number of double-fluorescent cells and
total number of cells positive with anti-Ti-yA.
with major differences from one donor to another ranging from <1 to 15%
(data not shown) .
Experiments that led to the discovery of y proteins have been based on the
observation thatcertain normal cloned fetal lymphocytes (1) as well as thymocytes
(5) or lymphocytes derived from immunodeficient patients (6) reacted with anti-
CD3 mAbs but not with anti-WT31, an mAb that recognizes a monomorphic
determinant of Ti-a/# (7). It was shown that at least a fraction of these CD3+
Ti-a/(#- cells surface-express polypeptides (3, 5, 6, 8-10) encoded by T cell
rearranging y genes (for review, see reference 11). Such findings supported the
view that a given T cell would carry either an a/(l, or alternatively, a 'r receptor
complex. Normal peripheral lymphocytes were therefore tested by two-color
immunofluorescence analysis with fluoresceinated anti-Ti-7A plus biotinylated
BMA-031, revealed by avidin-PE. In all five-donors tested, no double-labelled
cells were detected, demonstrating that expression of TCR a/,Q and Ti--YA
structures is mutually exclusive on peripheral lymphocytes (histograms from
three distinct donors are shown in Fig. 2A). We then studied the relationship
between the Ti-yA population and the well-characterized lymphocyte subsets
defined by individual expression of CD2, CD3, CD4, CD5, CD8, NKH1, and
MHC class II gene products. 10 healthy adults were tested. Two of them had
only 1% of Ti-yA+ lymphocytes, which made a quantitative analysis of double-
fluorescent cells rather inaccurate, in particular with second antibodies deline-
ating additional minor subsets such as anti-CD8 or anti-NKH1; they have not
been included in Table I, which summarizes the results obtained with the
remaining eight individuals, for whom the average anti-Ti-7A reactivity meas-
ured on the lymphocyte population was 6%, ranging from 3 to 15%.
>94% of Ti-yA+ cells expressed CD2 in all donors but one (Table 1). In this
latter individual only a minority of Ti-7A+ lymphocytes reacted with Coulter
clone CD2. Further studies will have to elucidate the significance of this obser-
vation . In seven donors, CD3 proteins were present on >95% of Ti-yA+ lym-
phocytes. In one case, anti-CD3 reacted with 92% ofTi-7A'' cells. This probably
reflects a technical artifact such as, for example, partial antibody release rather
Antigens
Mean
A
Range Mean -
B
Range Mean
C
Range Mean
D
Range
Ti-yA 6 3-15 - - -
CD2 77 56-85 5 2-15 7 3-17 89 36-99
CD3 71 65-77 6 2-15 9 3-21 97 92-99
CD4 41 24-51 <1 <1-1 <1 <1-2 5 <1-15
CD5 69 60-72 6 3-15 8 4-21 83 50-92
CD8 28 18-36 2 1-8 8 2-22 29 14-53
NKH1 12 3-18 <1 <1-3 8 1-24 13 6-30
Ia 6 3-9 <1 <1-1 7 2-14 7 2-19JITSUKAWA ET AL .
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FIGURE 2 . Double-color immunofluorescence analyses . Immunofluorescence experiments
were performed as described in Table I . Ordinate shows logo green fluorescence obtained
with fluoresceinated anti-Ti--yA antibody . Abscissa shows logo red fluorescence obtained with
the phyccerythrin-coupled mAb indicated in the figure . 3.0 x 10' cells were analyzed in each
sample . A represents three distinct donors . B shows histograms obtained with a unique
representative donor . C shows reactivity obtained in three distinct individuals with anti-CD8
antibody .
than a true surface expression of y chains without CD3 proteins . Virtually all
CD4+ lymphocytes were found to be Ti-yA- . There always was a small minority
of Ti-yA+ cells unreactive with anti-CD5 . Moreover, as opposed to CD2 and
CD3 (Fig . 2B), expression ofCD5 was weak on Ti-,yA+ cells .
Analysis with anti-CD8 led to the most heterogeneous results . For example,
two individuals had <20% of CD8'' cells in their Ti-yA' population, while in
one donor, a majority of Ti-yA+ cells were CD8' (Table 1) . CD8 density was
always weak on Ti-,yA+ cells (see Fig . 2C, which shows representative histograms
obtained with three distinct normal individuals) . Thus, an accurate delineation
of at least one subset of peripheral lymphocytes expressing Ti-,y chains cannot1196
￿
JITSUKAWA ET AL.
￿
BRIEF DEFINITIVE REPORT
be based on the lack of expression of both CD4 and CD8 proteins. Anti-NKH 1
(12) was found not to react with most Ti-yA+ lymphocytes. When some reactivity
was detected, it was weaker than that observed on CD3- NK cells. Finally, most
Ti-yA' cells were found not to express class 11 MHC gene products, supporting
the view that these lymphocytes are in a resting state.
Because a minority of CD3+, WT31 - clones that we have derived from
peripheral blood are Ti-7A-, it is most likely that the corresponding antibody
does not detect all circulating lymphocytes with y receptors. We have tried here
to delineate the fraction of TCR y+ cells, which are recognized by anti-Ti-7A
assuming, as a working hypothesis, that all CD3+ TCR-a/#- lymphocytes express
at least one y protein. For this purpose, we used the OKT3 mAb to detect cells
expressing CD3 proteins and the BMA-031 mAb to detect cells expressing an
a/,8 receptor. In the lymphocyte fraction isolated from an additional series of
nine healthy donors, there were 6% (range, 1-12%) more OKT3+ than BMA-
031' cells, while the mean reactivity of anti-Ti-yA was 4% (range, 1-10%).
Further studies will have to elucidate the relationship between this predomi-
nant subpopulation of TCR-y+ lymphocytes and the remaining CD3+ TCR-a/,0-
Ti-yA- cells. In this regard, it should be of particular interest to identify the
gene coding for the Ti-7A epitope (most likely, it is neither a C-yl or a C-y2
segment, because our CD3+ TCR-a/#- Ti-yA- clones express disulfide-linked
dimers as well as CD3+ Ti-yA+ cells). Furthermore, anti-Ti-yA mAb may help
to study potential structural differences between CD3-associated 'Y complexes,
which appear to include, in many cases, at least one additional still poorly
characterized protein designated S (or X) (6, 8-10, 13). Finally, the delineation
of this novel subset should allow us to better characterize the biological role of
TCR-y+ cells, and to determine whether protein products of T cell y rearranging
genes are involved as receptors directing functional activities such as, for exam-
ple, non-MHC-restricted killing.
Summary
We have previously characterized a CD3+ T cell receptor (TCR) a/#- human
fetal cloned cell line, termed F6C7, which surface-expresses a CD3-associated y
chain identified by anti-NKFi, an mAb with a restricted clonotypic reactivity.
Here, we have produced an additional antibody, anti-Ti-yA, which recognizes a
public epitope of the y molecule defined by anti-NKFi. Ti-yA is present on -r3%
ofcirculating lymphocytes with a wide range (1-15%) among 30 healthy individ-
uals tested. Two-color immunofluorescence experiments performed with anti-
Ti-yA and BMA 031 mAb (a reagent specific for the TCR-a/,B receptor) showed
that surface expression of Ti-a/fl and Ti-yA is mutually exclusive. Moreover, it
was found that most Ti-yA+ cells are CD2+, CD3+, CD4-, CD5+, NKH1-, HLA
class II-negative. In contrast, the expression of the CD8 molecule on these T
lymphocytes appears to be variable from one individual to another. Finally, we
found that Ti-yA+ cells represent a majority of peripheral lymphocytes that
express CD3 proteins but not the TCR-a/,# heterodimer. The delineation of this
unique lymphocyte subset should help further studies on the biology of cells with
a CD3-associated y complex.
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